Dyadic - Stock Price History | DYAI

Historical daily share price chart and data for Dyadic since 2021 adjusted for splits. The latest closing stock price for Dyadic as of October 22, 2021 is 4.50.
  • The all-time high Dyadic stock closing price was 10.26 on June 22, 2020.
  • The Dyadic 52-week high stock price is 8.78, which is 95.1% above the current share price.
  • The Dyadic 52-week low stock price is 3.15, which is 30% below the current share price.
  • The average Dyadic stock price for the last 52 weeks is 5.10.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Dyadic Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 6.7052 5.2700 10.2600 2.5800 5.3800 3.86%
2019 5.5988 3.5500 6.9500 3.2600 5.1800 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.126B $0.002B
Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms including humans found in the earth's biodiversity. Using its integrated technology platform, Dyadic develops biological products such as proteins, enzymes, polypeptides and small molecules for applications in large segments of the agricultural, industrial, chemical and biopharmaceutical industries. By utilizing a proprietary host organism, Dyadic's `one-stop shop` technology rapidly discovers and expresses eukaryotic genes the genes of complex living organisms and then manufactures those unique biological products for commercial application. Dyadic's systems overcome the inadequacy of existing gene discovery and product development techniques.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76